Biogen Patent Ruling Would Have a Limited Affect on the Stock, Analyst Says

[NewsFeeder]

Biogen Patent Ruling Would Have a Limited Affect on the Stock, Analyst Says

Multiple sclerosis treatment Tecfidera has been Biogen’s top seller since 2015. If the patent holds up, the company could maintain exclusivity until early 2028.

https://finance.yahoo.com/m/fb532c2...be1/biogen-patent-ruling-would.html?.tsrc=rss